Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, alongside a robust commitment to R&D and international expansion [1][2][3]. Financial Performance - The company achieved operating revenue of 16.743 billion yuan and a net profit of 5.069 billion yuan for the first half of 2025 [1]. - The net cash flow from operating activities was 3.922 billion yuan [1]. - The total cash dividend for 2025 is projected to reach 3.298 billion yuan, representing 65.06% of the net profit for the period [1]. International Business Growth - International business revenue reached 8.332 billion yuan, accounting for 50% of total revenue, with a year-on-year growth of 5.39% [3]. - Revenue from developing countries was 5.435 billion yuan, maintaining a two-thirds share of international business revenue [3]. - The company expects accelerated growth in international business in the second half of 2025, driven by local platform development and high-end customer acquisition [3]. Domestic Market Dynamics - Domestic business revenue was 8.411 billion yuan, impacted by delayed medical equipment tenders from the previous year, but is expected to recover in the third quarter of 2025 [2][6]. - The company anticipates a significant improvement in domestic market conditions due to the revival of medical equipment tender activities [6]. R&D Investment - The company maintained high R&D investment of 1.777 billion yuan, representing 10.61% of total revenue for the first half of 2025 [2][8]. - The company has filed a total of 12,240 patents, with 8,818 being invention patents, indicating a strong focus on innovation [2]. Product Line and Market Position - The company has a comprehensive product line across three main business areas: in vitro diagnostics, life information and support, and medical imaging [3][4]. - The in vitro diagnostics segment generated revenue of 6.424 billion yuan, with international business showing double-digit growth [4]. - The life information and support segment achieved revenue of 5.479 billion yuan, with international business contributing 67% of the total [5]. Future Outlook - The global medical device market is projected to grow from $623 billion in 2024 to $869.7 billion by 2030, with a compound annual growth rate of 5.7% [5]. - The company is well-positioned to capitalize on market opportunities through innovation and strategic expansion [10].

Core Insights - Mindray Medical reported a revenue of 16.743 billion yuan and a net profit attributable to shareholders of 5.069 billion yuan for the first half of 2025 [1] Group 1: International Business Performance - The company's international business generated revenue of 8.332 billion yuan, accounting for 50% of total revenue, with rapid growth in developing countries [1] - Mindray maintains a top-three market share globally in products such as monitors, anesthesia machines, ventilators, defibrillators, blood cell analyzers, and ultrasound products [1] - The company anticipates accelerated growth in international business in the second half of 2025, particularly in the in-vitro diagnostics segment [1] Group 2: Domestic Business Outlook - With the recovery of medical equipment bidding activities in the first half of 2025, the domestic market is expected to see a turning point in the third quarter [1] - Preliminary estimates suggest that the company's overall revenue will achieve year-on-year growth in the third quarter, continuing a trend of quarter-on-quarter improvement in revenue [1]

（文章来源：新华财经） 迈瑞医疗公告，公司2025年上半年实现营业收入167.43亿元，同比下降18.45%；归属于上市公司股东的 净利润为50.69亿元，同比下降32.96%；公司拟向全体股东每10股派发现金红利13.10元（含税）。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，迈瑞医疗发布公告称，2025年上半年实现营业 收入167.43亿元，同比下降18.45%；归属于上市公司股东的净利润为50.69亿元，同比下降32.96%；归 属于上市公司股东的扣除非经常性损益的净利润为49.49亿元，同比下降32.94%。 ...

深圳迈瑞生物医疗电子股份有限公司 信息披露暂缓和豁免管理制度 第一章 总则 第二章 暂缓、豁免披露信息的范围 第五条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息涉及国家秘 密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下统称 1 第一条 为规范深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资者合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披 露管理办法》《上市公司信息披露暂缓与豁免管理规定》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律、法规、规范性文件以及《深圳迈瑞生物医疗 电子股份有限公司章程》（以下简称"《公司章程》"）等有关规定，结合公司 的实际情况，特制定本制度。 第二条 公司和其他信息披露义务人按照相关法律法规及深圳证券交易所（以下简称 "深交所"）相关业务规则的规定，暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和深交所规定或者要求披露的 内容，适用本制度。 第 ...

Financial Performance - Total revenue for the first half of 2025 reached 167.4 billion CNY, with a net profit of 50.7 billion CNY [1] - Total assets amounted to 587.7 billion CNY, and net assets were 440.2 billion CNY [1] - The company anticipates positive year-on-year revenue growth in Q3 2025, continuing a trend of quarterly improvement [1] Shareholder Returns - The company announced a cash dividend of 17.1 billion CNY (before tax) for the first mid-term distribution in April 2025 [1] - A second mid-term cash dividend of 15.9 billion CNY (before tax) is planned for August 2025 [1] - The annual profit distribution will be at least 65% of the distributable profit [1] Business Segments In Vitro Diagnostics - Revenue from in vitro diagnostics reached 64.2 billion CNY, accounting for 38.4% of total revenue, with a double-digit year-on-year growth [1] - International chemical luminescence business grew by over 20% year-on-year [1] - The company sold 13 sets of the MT 8000 fully automated laboratory intelligent assembly line, with a total of 15 sets sold [1] Medical Imaging - Revenue from medical imaging was 33.1 billion CNY, representing 19.8% of total revenue [1] - The company has established a strong presence in the international market, with significant growth expected in Q3 2025 [3] Life Information and Support - Revenue from life information and support reached 54.8 billion CNY, making up 32.7% of total revenue [1] R&D and Innovation - R&D investment for the reporting period was 17.8 billion CNY, constituting 10.6% of total revenue [3] - The company has applied for a total of 12,240 patents, with 6,126 granted, including 3,085 invention patents [3] Market Expansion - The "瑞检生态" smart laboratory solution has been installed in nearly 800 hospitals, with 80% being tertiary hospitals [4] - The company has expanded its international footprint, with installations in countries like Jordan, Indonesia, Thailand, and Romania [7] Sustainable Development - The company maintained an MSCI ESG rating of AA for the third consecutive year and was included in the S&P Global Sustainable Development Yearbook (China Edition) [15] - Over 230,000 individuals participated in emergency training, with 9,008 people trained in 201 events [15]

人民财讯8月27日电，迈瑞医疗（300760）8月27日晚间披露半年报，2025年上半年，公司实现营业收入 167.43亿元，同比下降18.45%；归母净利润50.69亿元，同比下降32.96%；基本每股收益4.184元；拟每 10股派发现金红利13.1元(含税)。经公司初步测算，第三季度整体营业收入将实现同比正增长，同时延 续营业收入金额逐季度环比改善的趋势。其中：国际市场第三季度同比增长加速，国际体外诊断产线有 望实现较快增长；国内市场将明显改善，如期迎来拐点。 ...

Core Viewpoint - Mindray Medical reported a decline in both revenue and net profit for the first half of the year, indicating potential challenges in the company's financial performance [1] Financial Performance - The company achieved a revenue of 16.743 billion yuan in the first half of the year, representing a year-on-year decrease of 18.45% [1] - The net profit attributable to shareholders of the listed company was 5.069 billion yuan, down 32.96% year-on-year [1] - The basic earnings per share were reported at 4.184 yuan [1]

深圳迈瑞生物医疗电子股份有限公司 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-031 2025年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第2号—— 创业板上市公司规范运作》等相关规定，现将深圳迈瑞生物医疗电子股份有限公司（以下 简称"公司"）2025年半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"证监会"）签发的《关于核准深圳迈瑞生物 医疗电子股份有限公司首次公开发行股票的批复》（证监许可[2018] 1436号文），公司于2018 年10月向社会公众发行人民币普通股121,600,000股，每股发行价格为人民币48.80元，募集 资金总额为人民币5,934,080,000.00元。扣除承销保荐费用人民币138,396,226.41元，实际收 到募集资金人民币5,795,683,773.59元。扣除发行中介费用人民币43,884,311.43元后，实际募 集资金净 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-033 经深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）初步测算，公司 2025 年 第三季度整体营业收入将实现同比正增长，同时延续营业收入金额逐季度环比改善的趋势。 其中：国际市场第三季度同比增长加速，国际体外诊断产线有望实现较快增长；国内市场 将明显改善，如期迎来拐点。 二、变动原因说明 虽然国内市场医疗设备招标自去年 12 月开始复苏，但由于从公开招标到收入确认的周 期被显著拉长，因此国内业绩从今年三季度开始才迎来拐点。 三、其他相关说明 公司未就本次主要经营情况事项与会计师事务所进行预沟通，数据未经会计师事务所 审计。上述情况是公司进行初步测算的结果，具体数据以公司 2025 年第三季度报告中披露 的为准，且仅作为阶段性经营情况说明供投资者参考，不构成业绩承诺，不能以此推算公 司全年业绩情况。敬请投资者理性投资，注意风险。 特此公告。 深圳迈瑞生物医疗电子股份有限公司董事会 2025 年 8 月 28 日 深圳迈瑞生物医疗电子股份有限公司 2025年第三季度主要经营情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， ...